Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study-Reference-Cited by-同舟云学术

Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study

Published:2023-12-14 Issue:1 Volume:13 Page:153-164
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Millán-Pascual Jorge^ORCID,Valero-López Gabriel,Iniesta-Martinez Francisca,Hellin-Gil Maria Fuensanta,Jimenez-Veiga Judith,López-Tovar Isabel Alejandra,Morales-Ortiz Ana,Meca-Lallana José. E.^ORCID

Funder

Springer Healthcare Spain

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00572-8.pdf

Reference26 articles.

1. Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022;98(5):e541–54. https://doi.org/10.1212/WNL.0000000000013108.

2. The Spanish Agency of Medicines and Medical Devices (AEMPS). Comirnaty (BNT162b2, BioNTech/Pfizer): summary of product characteristics. 2020. https://cima.aemps.es/cima/pdfs/es/ft/1201528001/FT_1201528001.pdf. Accessed 26 Apr 2023.

3. The Spanish Agency of Medicines and Medical Devices (AEMPS). Spikevax (mRNA-1273, Moderna): summary of product characteristics. 2021. https://cima.aemps.es/cima/pdfs/es/ft/1201507001/FT_1201507001.pdf. Accessed 26 Apr 2023.

4. The Spanish Agency of Medicines and Medical Devices (AEMPS). Vaxzevria (ChAdOx1-S, AstraZeneca): summary of product characteristics. 2021. https://cima.aemps.es/cima/pdfs/es/ft/1211529001/FT_1211529001.pdf. Accessed 26 Apr 2023.

5. The Spanish Agency of Medicines and Medical Devices (AEMPS). Jcovden (Ad26COVS1, Janssen): summary of product characteristics. 2021. https://cima.aemps.es/cima/pdfs/es/ft/1201525001/FT_1201525001.pdf. Accessed 26 Apr 2023.